Cost Effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 11/06/2010 | 03/11/2010 | Reimbursement not recommended. |
We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.